AMNEAL PHARMACEUTICALS, INC. Finite-lived Intangible Assets Acquired
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Finite-lived Intangible Assets Acquired of $57.00 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-08.
Discontinued › Notes › Goodwill and Other
us-gaap:FinitelivedIntangibleAssetsAcquired1 · last filed 2022-11-07
- AMNEAL PHARMACEUTICALS, INC. finite-lived intangible assets acquired for the quarter ending 2021-09-30 was $57.00M.
- AMNEAL PHARMACEUTICALS, INC. finite-lived intangible assets acquired for the quarter ending 2021-06-30 was $73.80M.
- AMNEAL PHARMACEUTICALS, INC. finite-lived intangible assets acquired for the quarter ending 2021-03-31 was $131.00M, a 4.38% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. finite-lived intangible assets acquired for the quarter ending 2020-09-30 was $0.00.
| Period end | Finite-lived Intangible Assets Acquired 3 month | Finite-lived Intangible Assets Acquired 3 month as first filed | Finite-lived Intangible Assets Acquired 6 month | Finite-lived Intangible Assets Acquired 6 month as first filed | Finite-lived Intangible Assets Acquired 9 month | Finite-lived Intangible Assets Acquired 9 month as first filed |
|---|---|---|---|---|---|---|
| 2021-09-30 | $57.00M 10-Q · filed 2021-11-08 | $130.80M derived: sum of 2 quarters · filed 2022-08-08 | $56.40M 10-Q · filed 2022-11-07 | $57.00M 10-Q · filed 2021-11-08 | ||
| 2021-06-30 | $73.80M 10-Q · filed 2022-08-08 | $74.00M 10-Q · filed 2021-08-09 | $73.80M 10-Q · filed 2022-08-08 | $74.00M 10-Q · filed 2021-08-09 | ||
| 2021-03-31 | $131.00M 10-Q · filed 2021-05-07 | |||||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$6.00M derived: sum of 2 quarters · filed 2021-11-08 | $131.00M 10-Q · filed 2021-11-08 | |||
| 2020-06-30 | -$6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $131.00M 10-Q · filed 2021-08-09 | ||||
| 2020-03-31 | $137.00M 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |